NASDAQ$PRQR

ProQR Therapeutics NV · Q1 2017 earnings

Q1 2017 earnings · · Investor relations

Headline financials

Total Revenue

€2.28M

Previous: €9.41M-75.7%
EPS (adj)

-€0.41

Previous: -€0.29-41.4%
Net Income

-€10.5M

Previous: -€9.96M-5.2%
Operating Income

-€9.94M

Previous: -€10.6M+6.5%
Gross Profit

€0.00

Previous: €0.00
R&D Expense

€8.03M

Previous: €8.61M-6.7%

Revenue & EPS history

ProQR · Revenue · Quarterly

€2.28M

Q1 2017-75.7%vs Q1 2016
Beat estimate in 0 of 4 quarters(0%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports · overlaid with Q1 2017

Historical avgQ1 2017

-3.4%

Avg return

Earnings day

+0.5%

Avg return

5 days after

-1.6%

Avg return

30 days after

25%

5 / 20 earnings

Positive

+9.3%

Q2 2024

Best reaction

-29.3%

Q4 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.8%-1.2%-11.2%
Q3 2025-6.8%-9.2%-12.2%
Q2 2025+0.0%+5.5%+15.3%
Q4 2024-2.4%-15.2%-6.7%
Q3 2024+3.6%+9.3%-2.2%
Q2 2024+9.3%+9.8%+1.4%
Q1 2024-4.4%-3.5%-15.3%
Q4 2023+5.1%+2.3%+9.1%
Q3 2023-3.8%+0.0%-7.7%
Q1 2018-8.7%-4.3%-10.9%
Q4 2017-1.6%+5.6%-9.7%
Q1 2017+0.0%+5.0%+26.3%
Q3 2016-4.5%+1.9%+2.6%
Q2 2016-19.9%
Q1 2016+8.9%
Q4 2015-29.3%
Q3 2015-6.1%
Q2 2015-2.5%
Q1 2015-5.8%
Q3 2014+5.4%
Q2 2014
Q1 2014
Q4 2013
Q3 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro